Global Microbiome Therapeutics & Diagnostics Market Analysis & Forecast to 2023
- ID:PD031567
- September 2018
- Kelly Scientific Publications
Single User License: $4,900.00
Multi User License:
Enterprise License: $14,700.00
This report provides a comprehensive overview of the size of the microbiome therapeutic and diagnostic market, segmentation of the market (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin), key players and the potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global microbiome therapeutic and diagnostic market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023. The majority of the market will be dominated by microbiome based therapeutics, with an estimate of x%, compared to x% in microbiome diagnostics. This report describes the evolution of such a prospective market in eight chapters supported by over 82 tables and figures in 165 pages.
• An overview of the human microbiome space that includes how the market is sub-divided into therapeutics (prebiotics, probiotics, fecal microbiota transplantation, small molecules) and diagnostics.
• Global microbiome market, global breakdown, application breakdown and leading market players
• Detailed account of the microbiome industry market by geography, indication and company profiles
• Profiles, pipeline products, financial analysis and business strategy of the major companies in this space
• Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for microbiome therapeutics and diagnostics
• Insight into the challenges faced by stakeholders
• Insight into the biobanking industry globally and its impact on the overall market
• Description and data for the prevalence of disease types that are addressed by harnessing the human microbiota
• Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective
• SWOT analysis of the global market
• Geographical analysis and challenges within key topographies including North America, Europe, Asia/Pacific, Middle East/Africa, ROW
Countries Covered
Global,North America, Europe, Asia/Pacific, Middle East/Africa, ROC
Competitive Landscape
The microbiome field is highly competitive, especially within the inflammatory bowel disease and Clostridium difficile infection therapeutic markets. A wide range of big pharma, biotech, early-stage companies, academic institutions, government agencies and other public and private research organizations are involved in this space. The main therapeutic competitors within the microbiome industry are as follows:
• Johnson & Johnson
• Novartis International
• Abbvie
• Takeda
• Merck & Co.,
• Bristol Myers Squibb
• Pfizer
• Seres Therapeutics
• Vedanta Biosciences
• Finch Therapeutics
• Enterome Bioscience
• Second Genome
More specifically, companies involved in C. difficile infection include Actelion Pharmaceutical, Assembly Biosciences, AzurRx, Da Volterra, Pfizer, Merck, Merus, Rebiotix, Sanofi, Seres Therapeutics, Synthetic Biologics and Summit Therapeutics. Companies within the IBS-Constipation market include Ardelyx, Allergan, Ironwood Pharmaceuticals, Synergy Pharmaceuticals, Synthetic Biologics and Takeda. Within the pertussis market GlaxoSmithKline, Mitsubishi Tanabe Pharma Corporation and Sanofi are major players. BioMarin Pharmaceutical, Synthetic Biologics, Codexis and Synlogic are involved in the PKU market. Within the diagnostic sub-market, the following are the main players:
• Metabiomics - Colon Polyp and Colon Cancer Test
• Origin Sciences - Colorectal Cancer (CRC) Test
• Enterome/AbbVie - IBD110
• An overview of the human microbiome space that includes how the market is sub-divided into therapeutics (prebiotics, probiotics, fecal microbiota transplantation, small molecules) and diagnostics.
• Global microbiome market, global breakdown, application breakdown and leading market players
• Detailed account of the microbiome industry market by geography, indication and company profiles
• Profiles, pipeline products, financial analysis and business strategy of the major companies in this space
• Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for microbiome therapeutics and diagnostics
• Insight into the challenges faced by stakeholders
• Insight into the biobanking industry globally and its impact on the overall market
• Description and data for the prevalence of disease types that are addressed by harnessing the human microbiota
• Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective
• SWOT analysis of the global market
• Geographical analysis and challenges within key topographies including North America, Europe, Asia/Pacific, Middle East/Africa, ROW
Countries Covered
Global,North America, Europe, Asia/Pacific, Middle East/Africa, ROC
Competitive Landscape
The microbiome field is highly competitive, especially within the inflammatory bowel disease and Clostridium difficile infection therapeutic markets. A wide range of big pharma, biotech, early-stage companies, academic institutions, government agencies and other public and private research organizations are involved in this space. The main therapeutic competitors within the microbiome industry are as follows:
• Johnson & Johnson
• Novartis International
• Abbvie
• Takeda
• Merck & Co.,
• Bristol Myers Squibb
• Pfizer
• Seres Therapeutics
• Vedanta Biosciences
• Finch Therapeutics
• Enterome Bioscience
• Second Genome
More specifically, companies involved in C. difficile infection include Actelion Pharmaceutical, Assembly Biosciences, AzurRx, Da Volterra, Pfizer, Merck, Merus, Rebiotix, Sanofi, Seres Therapeutics, Synthetic Biologics and Summit Therapeutics. Companies within the IBS-Constipation market include Ardelyx, Allergan, Ironwood Pharmaceuticals, Synergy Pharmaceuticals, Synthetic Biologics and Takeda. Within the pertussis market GlaxoSmithKline, Mitsubishi Tanabe Pharma Corporation and Sanofi are major players. BioMarin Pharmaceutical, Synthetic Biologics, Codexis and Synlogic are involved in the PKU market. Within the diagnostic sub-market, the following are the main players:
• Metabiomics - Colon Polyp and Colon Cancer Test
• Origin Sciences - Colorectal Cancer (CRC) Test
• Enterome/AbbVie - IBD110
Chapter 1 Executive Summary
1.1 Synopsis
1.2 Objective of Report
1.3 Executive Summary
1.4 Key Questions Answered
1.5 Data Sources & Methodology
Chapter 2 Microbiome Overview
2.1 Microbiome Overview
2.2 Human Microbiome in Health and Disease
2.2.1 Cancer
2.2.2 Obesity
2.2.3 Microbiota Metabolism
2.2.3 Type 2 Diabetes Mellitus
2.2.4 Ulcerative Colitis and Crohn’s Disease
2.2.5 Clostridium Difficile Infection
2.2.6 Lactose Intolerance
2.2.7 CNS Disorders (gut brain axis)
2.2.8 Dental caries
2.2.9 Recurrent Bacterial Vaginosis and Urinary Tract Infection
2.2.10 Skin Diseases
2.2.11 Hyperoxaluria
2.2.12 Urea Cycle Disorder
2.2.13 Celiac Disease
2.2.14 Non-alcoholic Steatohepatitis (NASH)
2.2.15 Hepatic Encephalopathy
2.3 Types of Microbiome therapeutics
2.3.1 Prebiotics
2.3.2 Live BioTherapeutic Agents (Probiotics)
2.3.3 Fecal Microbiota Transplantation (FMT)
2.3.4 Small Molecules
2.4 Advances in Microbiome Research
2.4.1 MetaHIT Consortium
2.4.2 Human Microbiome Project
2.4.3 Functional Metagenomics
2.4.4 Microbiome Metabolomics
2.4.5 Identifying Microbiome Targets – Enterome EB8018 Case Study
2.5 Geographical Variation of Microbiome Composition
Chapter 3 Human Therapeutic and Diagnostic Pipeline Analysis
3.0 Synopsis
3.1 Clostridium Difficile
3.1.1 SER-109 Seres Therapeutics
3.1.2 SER-262 Seres Therapeutics
3.1.3 RBX2660 Rebiotix
3.1.4 VE303 Vedanta Biosciences
3.1.5 IMM-529 Immuron
3.1.6 MET-2 NuBiyota
3.1.7 CP101 Finch Therapeutics
3.1.8 ABI-M101 Assembly Biosciences
3.1.9 CBM-588 Osel
3.1.10 SYN-004 Synthetic Biologics
3.1.11 SYN-006 Synthetic Biologics
3.2 Ulcerative Colitis
3.2.1 FIN-524 Finch Therapeutics
3.2.2 SER-287 Seres Therapeutics
3.2.3 ABI-M201 Assembly Biosciences
3.3 Crohn’s Disease
3.3.1 ABI-M301 Assembly Biosciences
3.3.2 Thetanix 4D Pharma
3.4 Inflammatory Bowel Disease
3.4.1 SER-301 Seres Therapeutics
3.4.2 SGM-1019 Second Genome
3.4.3 Blautix 4D Pharma
3.4.4 SG-2-0776 Second Genome
3.4.5 IBD110 – Enterome/AbbVie
3.5 Immuno-Oncology
3.5.1 SER-401 Seres Therapeutics
3.5.2 Colon Polyp & Colon Cancer Test - Metabiomics
3.5.3 Colorectal Cancer (CRC) Test – Origin Sciences
3.6 Graft Versus Host Disease
3.6.1 SER-155 Seres Therapeutics
3.7 Urinary Tract Infections
3.7.1 LACTIN-V Osel
3.8 Liver Disease
3.8.1 SGM-1019 Second Genome
3.9 Phenylketoneuria
3.9.1 SYNB1020 Synlogic
3.9.2 SYNB1618 Synlogic
Chapter 4 Market Analysis & Forecast to 2023
4.0 Synopsis
4.1 Market Applications
4.1.1 Clostridium Difficile Infection
1.1 Synopsis
1.2 Objective of Report
1.3 Executive Summary
1.4 Key Questions Answered
1.5 Data Sources & Methodology
Chapter 2 Microbiome Overview
2.1 Microbiome Overview
2.2 Human Microbiome in Health and Disease
2.2.1 Cancer
2.2.2 Obesity
2.2.3 Microbiota Metabolism
2.2.3 Type 2 Diabetes Mellitus
2.2.4 Ulcerative Colitis and Crohn’s Disease
2.2.5 Clostridium Difficile Infection
2.2.6 Lactose Intolerance
2.2.7 CNS Disorders (gut brain axis)
2.2.8 Dental caries
2.2.9 Recurrent Bacterial Vaginosis and Urinary Tract Infection
2.2.10 Skin Diseases
2.2.11 Hyperoxaluria
2.2.12 Urea Cycle Disorder
2.2.13 Celiac Disease
2.2.14 Non-alcoholic Steatohepatitis (NASH)
2.2.15 Hepatic Encephalopathy
2.3 Types of Microbiome therapeutics
2.3.1 Prebiotics
2.3.2 Live BioTherapeutic Agents (Probiotics)
2.3.3 Fecal Microbiota Transplantation (FMT)
2.3.4 Small Molecules
2.4 Advances in Microbiome Research
2.4.1 MetaHIT Consortium
2.4.2 Human Microbiome Project
2.4.3 Functional Metagenomics
2.4.4 Microbiome Metabolomics
2.4.5 Identifying Microbiome Targets – Enterome EB8018 Case Study
2.5 Geographical Variation of Microbiome Composition
Chapter 3 Human Therapeutic and Diagnostic Pipeline Analysis
3.0 Synopsis
3.1 Clostridium Difficile
3.1.1 SER-109 Seres Therapeutics
3.1.2 SER-262 Seres Therapeutics
3.1.3 RBX2660 Rebiotix
3.1.4 VE303 Vedanta Biosciences
3.1.5 IMM-529 Immuron
3.1.6 MET-2 NuBiyota
3.1.7 CP101 Finch Therapeutics
3.1.8 ABI-M101 Assembly Biosciences
3.1.9 CBM-588 Osel
3.1.10 SYN-004 Synthetic Biologics
3.1.11 SYN-006 Synthetic Biologics
3.2 Ulcerative Colitis
3.2.1 FIN-524 Finch Therapeutics
3.2.2 SER-287 Seres Therapeutics
3.2.3 ABI-M201 Assembly Biosciences
3.3 Crohn’s Disease
3.3.1 ABI-M301 Assembly Biosciences
3.3.2 Thetanix 4D Pharma
3.4 Inflammatory Bowel Disease
3.4.1 SER-301 Seres Therapeutics
3.4.2 SGM-1019 Second Genome
3.4.3 Blautix 4D Pharma
3.4.4 SG-2-0776 Second Genome
3.4.5 IBD110 – Enterome/AbbVie
3.5 Immuno-Oncology
3.5.1 SER-401 Seres Therapeutics
3.5.2 Colon Polyp & Colon Cancer Test - Metabiomics
3.5.3 Colorectal Cancer (CRC) Test – Origin Sciences
3.6 Graft Versus Host Disease
3.6.1 SER-155 Seres Therapeutics
3.7 Urinary Tract Infections
3.7.1 LACTIN-V Osel
3.8 Liver Disease
3.8.1 SGM-1019 Second Genome
3.9 Phenylketoneuria
3.9.1 SYNB1020 Synlogic
3.9.2 SYNB1618 Synlogic
Chapter 4 Market Analysis & Forecast to 2023
4.0 Synopsis
4.1 Market Applications
4.1.1 Clostridium Difficile Infection
Related Categories :
Biotechnology
www.decisiondatabases.com is a online aggregator of market and research database which includes databases, reports and profiles. We have started this portal with a aim to become one stop shop provider for marketing and research data requirements for various sector and country databases.
Main Categories
